Nutex Health, Inc.
NASDAQ:NUTXMedical - Healthcare Information Services
+$2.84 today
- Market cap
- $1.19B
- Beta
- 2.06
- P/E (TTM)
- 10.4
- EPS (TTM)
- $14.38
Volume 0.16M
Average 0.17M
NUTX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Nutex Health, Inc.NASDAQ: NUTX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 144.7% from a year ago
Cash & equivalents stood at $207.35M at the end of Q1 FY2026, up 144.7% from a year earlier and up 11.7% from the prior quarter. Over 3 fiscal years it compounded at +75.6% a year.
Context
- Cash & equivalents amounted to 21.7% of total assets at the end of Q1 FY2026, up 10.5 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +144.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 185.57M USD
- Year-over-year change
- +325.8%
- 4-year CAGR
- +50.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 185.57M | +325.8% |
| FY2024 | 2024-12-31 | 43.58M | +98.1% |
| FY2023 | 2023-12-31 | 22M | -35.8% |
| FY2022 | 2022-12-31 | 34.26M | -5.2% |
| FY2021 | 2021-12-31 | 36.12M | — |
Cash & Equivalents vs competitors
How NUTX compares with its peers on the latest reported figures
- NUTX's Mar 2026 cash & equivalents of $207.35M is the 6th highest of the 11 companies compared; the peer median is $247.24M.
- Its year-over-year change of +144.7% is the highest of 11, against a peer median of +40.6%.
- Cash & equivalents amounts to 21.7% of total assets for NUTX, versus a peer median of 6.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $2.17B | -17.3% | +49.8% | 7.1% | |
| Mar 2026 | $712M | +65.2% | +30.1% | 5.4% | |
ARDTArdent Health Partners, LLC | Mar 2026 | $609.69M | +23.2% | +15.9% | 11.6% |
| Mar 2026 | $478.38M | +85.0% | +14.2% | 20.3% | |
| Sep 2026 | $354.5M | +74.3% | -5.3% | 5.0% | |
| Mar 2026 | $207.35M | +144.7% | +75.6% | 21.7% | |
| Mar 2026 | $139.99M | +1.0% | -28.0% | 9.3% | |
| Jun 2026 | $138.8M | +0.9% | +10.3% | 0.9% | |
| Jun 2026 | $107.7M | -21.6% | +67.7% | 1.4% | |
| Mar 2026 | $95.55M | +58.0% | -29.7% | 17.5% | |
CONConcentra Group Holdings Parent, Inc. | Sep 2026 | $85.82M | +71.8% | +28.5% | 2.8% |
| Peer median (excluding NUTX) | $247.24M | +40.6% | +15.1% | 6.2% | |
Competitors are the stored peer set for NUTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 36.12M | 34.26M | 22M | 43.58M | 185.57M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 114.76M | 58.32M | 62.78M | 236.05M | 325.42M |
| Inventory | 2.81M | 3.53M | 3.39M | 2.85M | 2.87M |
| Other Current Assets | 323.28K | 1.87M | 2.68M | 10M | 24.95M |
| Total Current Assets | 154.02M | 97.97M | 90.85M | 292.48M | 538.81M |
| Property, Plant & Equipment (Net) | 238.36M | 295.15M | 269.39M | 324.69M | 343.9M |
| Goodwill | 1.14M | 17.01M | 17.07M | 13.92M | 13.92M |
| Intangible Assets | 682.65K | 21.19M | 20.51M | 15.53M | 21.23M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 7.99M | 0 |
| Other Non-current Assets | 456.09K | 423.43K | 431.14K | 711.35K | 662K |
| Total Non-current Assets | 240.63M | 333.78M | 307.4M | 362.84M | 379.71M |
| Total Assets | 394.65M | 431.75M | 398.25M | 655.32M | 918.53M |
| Account Payables | 17.65M | 23.93M | 25.28M | 13.96M | 48.97M |
| Short-term Debt | 10.23M | 15.17M | 14.18M | 17.95M | 14.08M |
| Tax Payables | 0 | 1.03M | 0 | 27.12M | 867K |
| Deferred Revenue | 173.92K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.6M | 5.61M | 0 | 0 | 8.26M |
| Total Current Liabilities | 37.69M | 54.86M | 58.31M | 140.87M | 157.91M |
| Long-term Debt | 78.82M | 23.05M | 26.31M | 22.47M | 29.17M |
| Deferred Tax Liabilities | 1.75M | 10.45M | 5.15M | 0 | 9.09M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | (1.75M) | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 165.38M | 256.56M | 260.83M | 312.56M | 337.18M |
| Total Liabilities | 203.07M | 311.42M | 319.14M | 453.43M | 495.09M |
| Common Stock | 592.79K | 650.22K | 676.68K | 5.51K | 7K |
| Retained Earnings | 102.32M | (363.29M) | (409.07M) | (356.89M) | (286.19M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 76.93M | 24.46M | 17.65M | 55.55M | 93.99M |
| Total Equity | 191.58M | 120.33M | 79.11M | 201.89M | 423.44M |
| Total Debt | 178.55M | 267.2M | 275.76M | 340.3M | 351.39M |
| Net Debt | 142.43M | 232.95M | 253.75M | 296.72M | 165.82M |
Nutex Health, Inc.
NASDAQ:NUTX
Intrinsic Alpha fair value
Locked
Current Price
$172.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.